Clinical Trials Browser

Observational × Peripheral Nervous System Diseases × Genitourinary × Clear all

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis

NCT02492360 2018-02-28

Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy

Withdrawn

Genitourinary

Peripheral Nervous System Diseases, Testicular Neoplasms

Clinical Trials

P-EVOLUTION

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy